You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

HAT3 peptide (ab41910)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

HAT3 peptide

Protein description

Synthetic peptide surrounding amino acid 1991 of human HAT3. This peptide was used as an immunogen for ab41718 - HAT3 antibody.

Properties

Purification notes

86% pure peptide.

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Storage buffer

Preservative: 0.02% Sodium Azide
Constituents: 0.1% BSA, PBS, pH 7.2

Concentration

Concentration information loading...

Applications

Show applications key

Our Abpromise guarantee covers the use of ab41910 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Blocking

     

Application notes

BL: Use at an assay dependent dilution. This peptide is used for blocking the antibody activity of HAT-3 (ab41718). It usually blocks the antibody activity completely in Western blot analysis by incubating the peptide with equal volume of antibody for 30 minutes at 37 degrees C.


Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.

Protein info

Function

Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. May act as a transcriptional coactivator for RUNX1 and RUNX2.

Involvement in disease

Note=Chromosomal aberrations involving MYST3 may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with CREBBP; translocation t(8;22)(p11;q13) with EP300. MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription. Inversion inv(8)(p11;q13) generates the MYST3-NCOA2 oncogene, which consists of the N-terminus part of MYST3/MOZ and the C-terminus part of NCOA2/TIF2. MYST3-NCOA2 binds to CREBBP and disrupts its function in transcription activation.
Note=A chromosomal aberration involving MYST3 is a cause of therapy-related myelodysplastic syndrome. Translocation t(2;8)(p23;p11.2) with ASXL2 generates a MYST3-ASXL2 fusion protein.

Sequence similarities

Belongs to the MYST (SAS/MOZ) family.
Contains 1 C2HC-type zinc finger.
Contains 1 H15 (linker histone H1/H5 globular) domain.
Contains 2 PHD-type zinc fingers.

Domain

The N-terminus is involved in transcriptional activation while the C-terminus is involved in transcriptional repression.

Post-translational
modifications

Autoacetylated.
Phosphorylated upon DNA damage, probably by ATM or ATR.

Cellular localization

Nucleus. Partially concentrated in subnuclear foci distinct from PML bodies, and excluded from the nucleoli.

Target information above from: UniProt accessionQ92794 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

References for HAT3 peptide (ab41910)

ab41910 has not yet been referenced specifically in any publications.

Publishing research using ab41910? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"